BioNexus Gene Lab CorpBioNexus Gene Lab CorpBioNexus Gene Lab Corp

BioNexus Gene Lab Corp

No trades
See on Supercharts
Market capitalization
‪10.67 M‬USD
−0.1608USD
‪−2.63 M‬USD
‪9.77 M‬USD
‪7.07 M‬
Beta (1Y)
1.07

About BioNexus Gene Lab Corp

CEO
Lee Su-Leng Tan
Headquarters
Kuala Lumpur
Employees (FY)
18
Founded
2017
ISIN
US0906282076
FIGI
BBG00N70PLY0
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BGLC is 0.5998 USD — it has decreased by 29.32% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioNexus Gene Lab Corp stocks are traded under the ticker BGLC.
BGLC stock is 46.31% volatile and has beta coefficient of 1.07. Check out the list of the most volatile stocks — is BioNexus Gene Lab Corp there?
Yes, you can track BioNexus Gene Lab Corp financials in yearly and quarterly reports right on TradingView.
BGLC stock has fallen by 7.01% compared to the previous week, the month change is a 21.75% fall, over the last year BioNexus Gene Lab Corp has showed a 86.85% decrease.
BGLC net income for the last quarter is ‪308.46 K‬ USD, while the quarter before that showed ‪−2.61 M‬ USD of net income which accounts for 111.82% change. Track more BioNexus Gene Lab Corp financial stats to get the full picture.
Today BioNexus Gene Lab Corp has the market capitalization of ‪10.67 M‬, it has increased by 4.13% over the last week.
No, BGLC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BGLC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioNexus Gene Lab Corp stock right from TradingView charts — choose your broker and connect to your account.
BGLC reached its all-time high on Oct 21, 2020 with the price of 41.4166 USD, and its all-time low was 0.3100 USD and was reached on Nov 15, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 21, 2024, the company has 18.00 employees. See our rating of the largest employees — is BioNexus Gene Lab Corp on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioNexus Gene Lab Corp technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioNexus Gene Lab Corp stock shows the sell signal. See more of BioNexus Gene Lab Corp technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioNexus Gene Lab Corp EBITDA is ‪−2.99 M‬ USD, and current EBITDA margin is −30.41%. See more stats in BioNexus Gene Lab Corp financial statements.